| 3 |
3
제1항에 있어서,miR-106b-5p, miR-10a-3p, miR-10a-5p, miR-125b-5p, miR-1285-3p, miR-130b-3p, miR-135b-5p, miR-138-5p, miR-141-3p, miR-141-5p, miR-143-5p, miR-145-5p, miR-150-5p, miR-15b-5p, miR-17-5p, miR-182-5p, miR-183-5p, miR-185-5p, miR-18a-5p, miR-199a-3p, miR-199a-5p, miR-199b-5p, miR-200a-3p, miR-200a-5p, miR-200b-3p, miR-200b-5p, miR-200c-3p, miR-205-3p, miR-205-5p, miR-20a-5p, miR-21-3p, miR-214-3p, miR-21-5p, miR-22-5p, miR-30a-3p, miR-30a-5p, miR-335-5p, miR-34c-5p, miR-411-5p, miR-425-5p, miR-429, miR-7-5p, miR-92a-3p, miR-93-3p, miR-93-5p, miR-96-5p 및 miR-99a-5p로 이루어진 군으로부터 선택되는 하나 이상의 miRNA 발현 수준을 측정하는 제제를 추가로 포함하는 것을 특징으로 하는 비근침윤성 방광암의 진단용 조성물
|
| 4 |
4
제1항에 있어서,ABCA8, ACTA2, ACTN1, ADAMTS1, ADAMTS8, AKAP12, ANTXR2, AOC3, ASF1B, ATP1A2, ATP8B2, AURKB, AXIN2, AXL, BCL2, BHMT2, BIN1, BNC2, BOC, C1S, CACHD1, CALD1, CAV1, CAV2, CCL19, CD14, CD1D, CD37, CD8A, CDC20, CDH11, CDKN1C, CELSR3, CENPM, CEP55, CFI, CGNL1, CHN1, CLIC4, CNN3, COL18A1, COL21A1, COL3A1, COL6A1, COL6A2, COLEC12, CPE, CREB5, CRISPLD2, CRTAP, CSF1R, CTGF, CYBRD1, CYGB, CYR61, CYTL1, CYYR1, DACH1, DACT1, DDR2, DENND2A, DKK3, DLG2, DNASE1L3, DOCK11, DPYSL2, DSTN, DTL, E2F2, EDNRA, EGR1, EGR2, EOMES, EPB41L2, EPB41L3, ESR1, F10, F3, FAM110B, FAM129A, FAM20C, FBLN2, FBLN5, FGF9, FGL2, FHL1, FILIP1L, FLNA, FNBP1, FOS, FZD1, FZD10, GABARAPL1, GAS1, GATA5, GFPT2, GJA1, GLT8D2, GNA14, GNG7, GPR124, GPR162, GSN, GZMK, HBB, HCST, HHIP, HLA-DRB5, HOXA9, IGFBP5, ITGA8, ITGB2, ITK, ITM2A, ITPR1, JAZF1, JUN, KATNAL1, KCNMB1, KDELC2, KIAA0513, KIAA1644, KLF2, KLF9, KLRB1, KRT7, LAMC2, LIFR, LITAF, LMO3, LMOD1, LPPR4, LTBP4, MAFB, MAOB, MAP1B, METTL7A, MFGE8, MGLL, MGP, MOXD1, MXRA8, MYH11, MYLK, NAALAD2, NFIB, NFIL3, NFIX, NKG7, NPTN, NR2F1, OLFML3, OTUD1, P2RX1, PALLD, PAPPA, PAX8, PCOLCE2, PDE5A, PDGFC, PDGFD, PDK4, PLA2G4A, PLSCR4, PODN, POLQ, PPAP2A, PPAP2B, PRDM8, PRICKLE1, PRICKLE2, PRNP, PROS1, PTGIS, PTRF, RAB23, RARRES2, RASD1, RECK, RERG, RHOB, RNASE4, RNF150, ROR2, RORB, RTN4, RUNX1T1, RUNX3, SCARA5, SCRG1, SERPINF1, SERPING1, SFRP1, SLC46A2, SMOC2, SNCA, SORBS2, SORCS2, STAT4, STMN3, SYNPO2, TAGLN, TCF21, TCF4, TGFB3, TGFBI, TGFBR2, TGM2, TIMP2, TLR1, TMEM119, TNC, TPM1, TPM2, TSC22D3, TSHZ3, TUBB2A, TYMS, UCHL1, VASN, VCAM1, VEGFA, VIM, VNN2, ZBTB16, ZEB2 및 ZFP36L1로 이루어진 군으로부터 선택되는 하나 이상의 유전자 발현 수준을 측정하는 제제를 추가로 포함하는 것을 특징으로 하는 비근침윤성 방광암의 진단용 조성물
|
| 10 |
10
제8항에 있어서,miR-106b-5p, miR-10a-3p, miR-10a-5p, miR-125b-5p, miR-1285-3p, miR-130b-3p, miR-135b-5p, miR-138-5p, miR-141-3p, miR-141-5p, miR-143-5p, miR-145-5p, miR-150-5p, miR-15b-5p, miR-17-5p, miR-182-5p, miR-183-5p, miR-185-5p, miR-18a-5p, miR-199a-3p, miR-199a-5p, miR-199b-5p, miR-200a-3p, miR-200a-5p, miR-200b-3p, miR-200b-5p, miR-200c-3p, miR-205-3p, miR-205-5p, miR-20a-5p, miR-21-3p, miR-214-3p, miR-21-5p, miR-22-5p, miR-30a-3p, miR-30a-5p, miR-335-5p, miR-34c-5p, miR-411-5p, miR-425-5p, miR-429, miR-7-5p, miR-92a-3p, miR-93-3p, miR-93-5p, miR-96-5p 및 miR-99a-5p로 이루어진 군으로부터 선택되는 하나 이상의 miRNA 발현수준을 측정하는 단계를 추가로 포함하는 것을 특징으로 하는 비근침윤성 방광암 진단을 위한 정보를 제공하는 방법
|
